Pharmafile Logo

global access

- PMLiVE

NICE recommends Ultomiris for NHS use in patients with rare blood disorders

aHUS is an ultra-rare and life-threatening disease that causes progressive injury to vital organs

Pharmerit rebrands to OPEN Health

OPEN Health is moving to one brand to create a world-class integrated services model

OPEN Health

Improving Public Health Through Telemedicine

Laurence Girard, CEO of Fruit Street Health, shares his tips for aspiring HealthTech entrepreneurs, his views on the future of telemedicine and digital health, and why he thinks healthcare companies...

Impetus Digital

Social Media, Wearable Technologies, and AI

João Bocas, CEO, Keynote Speaker, Social Media Influencer & Advisor at Digital Salutem, shares his thoughts on several intriguing topics related to wearables, AI, machine learning, robotics, and other digital...

Impetus Digital

Advancing Human Health Through Precise Measures of Movement, Cognition, & Biometrics

Scott McMillan, CEO of XCO, discusses wearable technologies for chronic and acute disease monitoring, virtual trials, and assessment of athlete performance. Among other things, we also dive into the role...

Impetus Digital

- PMLiVE

Lucid Group opens our new space in Marlow

This week marks an important step for everyone here at Lucid Group, as we re-open our premises in the UK and US and evolve to a hybrid way of working....

Lucid Group Communications Limited

- PMLiVE

Galderma unites rosacea sufferers from around the globe in an empowering social media awareness movement: #RosaceaUnmasked

Rosacea is a skin disease that affects an estimated 415 million people worldwide

- PMLiVE

Alzheimer’s disease: the search for a cure

To ensure the successful discovery and development of new dementia therapies, key gaps in the field need to be addressed

Gamification for patient care, medical education, and virtual engagement

“Gamification”–adding game-like elements into non-game or real-world settings–has become a popular concept in the pharmaceutical, healthcare, and event industries. However, it is proving more than a mere buzzword. With diverse...

Impetus Digital

- PMLiVE

FDA priority review granted for BeiGene’s Brukinsa for marginal zone lymphoma

The FDA submission for Brukinsa in MZL includes results from the phase 2 MAGNOLIA trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links